Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) insider Ingrid Delaet sold 1,431 shares of the company’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $107.52, for a total transaction of $153,861.12. Following the completion of the sale, the insider now directly owns 5,931 […]
Spire Wealth Management boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 203.2% during the 1st quarter, HoldingsChannel.com reports. The fund owned 379 shares of the company’s stock after buying an additional 254 shares during the quarter. Spire Wealth Management’s holdings in Neurocrine Biosciences were worth $38,000 as of its […]
Spire Wealth Management raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 203.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 379 shares of the company’s stock after buying an additional 254 shares during the period. Spire Wealth Management’s […]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) CFO Matt Abernethy sold 2,132 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $107.39, for a total transaction of $228,955.48. Following the transaction, the chief financial officer now directly owns 27,131 shares […]
Cantor Fitzgerald restated their overweight rating on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a report published on Tuesday morning, Benzinga reports. They currently have a $136.00 target price on the stock. Other analysts have also recently issued research reports about the company. SVB Leerink upgraded Neurocrine Biosciences from a market perform rating […]